Literature DB >> 26522453

Growth hormone binding protein - physiological and analytical aspects.

Katharina Schilbach1, Martin Bidlingmaier2.   

Abstract

A significant proportion of total circulating growth hormone (GH) is bound to a high affinity growth hormone binding protein (GHBP). Several low affinity binding proteins have also been described. Significant differences between species exist with respect to origin and regulation of GHBP, but generally it resembles the extracellular domain of the GH receptor. Concentrations are associated with GH status, body composition and other factors. Although the clinical relevance of GHBP is not fully understood it is suggested that concentrations indirectly reflect GH receptor status. This is supported by cases of Laron's syndrome where a molecular defect in the extracellular domain of the GH receptor is associated with low or unmeasurable GHBP concentrations. Methods to measure GHBP have evolved from chromatographic, activity based procedures to direct immunoassays. In clinical practice, measurement of GHBP can be helpful to differentiate between GH deficiency and GH insensitivity, particularly if GHBP is absent.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ectodomain shedding; growth hormone insensitivity; growth hormone receptor; immunoassay

Mesh:

Substances:

Year:  2015        PMID: 26522453     DOI: 10.1016/j.beem.2015.06.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  6 in total

Review 1.  Growth Hormone and Counterregulation in the Pathogenesis of Diabetes.

Authors:  Xuehong Dong; Lei Su; Mary-Elizabeth Patti
Journal:  Curr Diab Rep       Date:  2022-08-24       Impact factor: 5.430

Review 2.  Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease.

Authors:  Christoffer Soendergaard; Jonathan A Young; John J Kopchick
Journal:  Int J Mol Sci       Date:  2017-05-09       Impact factor: 5.923

3.  Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.

Authors:  Daniel B Hawcutt; Jennifer Bellis; Victoria Price; Anne Povall; Paul Newland; Paul Richardson; Matthew Peak; Jo Blair
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

4.  A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.

Authors:  Peter J Trainer; John D C Newell-Price; John Ayuk; Simon J B Aylwin; Aled Rees; William Drake; Philippe Chanson; Thierry Brue; Susan M Webb; Carmen Fajardo; Javier Aller; Ann I McCormack; David J Torpy; George Tachas; Lynne Atley; David Ryder; Martin Bidlingmaier
Journal:  Eur J Endocrinol       Date:  2018-05-22       Impact factor: 6.664

5.  iGHBP: Computational identification of growth hormone binding proteins from sequences using extremely randomised tree.

Authors:  Shaherin Basith; Balachandran Manavalan; Tae Hwan Shin; Gwang Lee
Journal:  Comput Struct Biotechnol J       Date:  2018-10-24       Impact factor: 7.271

6.  Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein.

Authors:  Ankur Rughani; Dongsheng Zhang; Kanimozhi Vairamani; Andrew Dauber; Vivian Hwa; Sowmya Krishnan
Journal:  Clin Endocrinol (Oxf)       Date:  2020-01-22       Impact factor: 3.478

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.